All things considered, differentiable criteria for comparisons were frequently taken into account when comparing cancer patients with different molecular features (e.g., HER2+ vs. HER2-; HER2+ vs. TNBC; Luminal vs. TNBC; Luminal vs. healthy controls; pre-therapy vs. post-therapy). This evidence concerns the gene ERBB2 and cancer.